Table 6 Overall impact of the MDR, n = 74
The MDR* has improved product traceability | Agree | Neither agree nor disagree | Disagree | ||
|---|---|---|---|---|---|
Enterprise size | Micro | n | 23 | 9 | 2 |
% | 67.6% | 26.5% | 5.9% | ||
Small | n | 21 | 3 | 2 | |
% | 80.8% | 11.5% | 7.7% | ||
Medium-sized | n | 4 | 3 | 1 | |
% | 50% | 37.5% | 12.5% | ||
Large | n | 6 | 0 | 0 | |
% | 100% | 0% | 0% | ||
The MDR has improved patient safety | |||||
Enterprise size | Micro | n | 23 | 4 | 7 |
% | 67.6% | 11.8% | 20.6% | ||
Small | n | 20 | 3 | 3 | |
% | 76.9% | 11.5% | 11.5% | ||
Medium-sized | n | 5 | 3 | 0 | |
% | 62.5% | 37.5% | 0% | ||
Large | n | 6 | 0 | 0 | |
% | 100% | 0% | 0% | ||
The MDR has increased transparency | |||||
Enterprise size | Micro | n | 21 | 8 | 5 |
% | 61.8% | 23.5% | 14.7% | ||
Small | n | 22 | 1 | 3 | |
% | 84.6% | 3.8% | 11.5% | ||
Medium-sized | n | 3 | 3 | 2 | |
% | 37.5% | 37.5% | 25% | ||
Large | n | 5 | 0 | 1 | |
% | 83.3% | 0% | 16.7% | ||
The MDR guarantees fair market access for enterprises | |||||
Enterprise size | Micro | n | 13 | 6 | 15 |
% | 38.2% | 17.6% | 44.1% | ||
Small | n | 10 | 5 | 11 | |
% | 38.5% | 19.2% | 42.3% | ||
Medium-sized | n | 3 | 3 | 2 | |
% | 37.5% | 37.5% | 25% | ||
Large | n | 5 | 1 | 0 | |
% | 83.3% | 16.7% | 0% | ||